Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 132
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | ||
| NCT02343952 | Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | ||
| NCT06863311 | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC | ||
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | ||
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | ||
| NCT05442216 | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | ||
| NCT06248606 | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | ||
| NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements | ||
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | ||
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | ||
| NCT00730353 | Sutent + Taxol for Advanced Esophageal Cancer | ||
| NCT00417248 | Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer | ||
| NCT03451331 | Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer | ||
| NCT07185945 | Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy | ||
| NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | ||
| NCT05406713 | Pembrolizumab in Muscle-invasive Bladder Cancer | ||
| NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") | ||
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | ||
| NCT00216151 | Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma | ||
| NCT00216099 | Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer | ||
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | ||
| NCT00216021 | Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer | ||
| NCT06493019 | Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | ||
| NCT02586610 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | ||
| NCT00216125 | Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer | ||
| NCT05956041 | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | ||
| NCT00773474 | Lonafarnib in Metastatic Breast Cancer | ||
| NCT02500901 | Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | ||
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | ||
| NCT05498272 | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | ||
| NCT06794229 | Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis | ||
| NCT07471841 | Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax | ||
| NCT03448718 | Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | ||
| NCT05467891 | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | ||
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | ||
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | ||
| NCT03099564 | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | ||
| NCT03840967 | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | ||
| NCT00379912 | Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes | ||
| NCT00572572 | Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors | ||
| NCT07218666 | Zanzalintinib in Men With Aggressive Variant Prostate Cancer | ||
| NCT01732107 | Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression | ||
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | ||
| NCT00216073 | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer | ||
| NCT00235235 | A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer | ||
| NCT02375672 | Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | ||
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | ||
| NCT00216086 | Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer | ||
| NCT03547999 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | ||
| NCT00613626 | Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer |
